- Home
- LI vs BBIO Comparison
LI vs BBIO Comparison
Compare LI & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LI | BBIO |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | China | United States |
| Employees | 30728 | N/A |
| Industry | Auto Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.3B | 14.2B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | LI | BBIO |
|---|---|---|
| Price | $17.77 | $70.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 25 |
| Target Price | $19.66 | ★ $86.04 |
| AVG Volume (30 Days) | ★ 2.6M | 2.2M |
| Earning Date | 05-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $502,076,000.00 |
| Revenue This Year | $18.98 | $89.45 |
| Revenue Next Year | $22.72 | $73.78 |
| P/E Ratio | $29.50 | ★ N/A |
| Revenue Growth | N/A | ★ 126.26 |
| 52 Week Low | $15.71 | $31.77 |
| 52 Week High | $32.03 | $84.94 |
Technical Indicators
Market Signals| Indicator | LI | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 43.39 | 43.63 |
| Support Level | $17.45 | $69.62 |
| Resistance Level | $18.94 | $78.96 |
| Average True Range (ATR) | 0.33 | 3.99 |
| MACD | -0.12 | -0.79 |
| Stochastic Oscillator | 20.90 | 14.62 |
Price Performance
Historical ComparisonAbout LI Li Auto Inc.
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 400,000 NEVs in 2025, accounting for about 3% of China's passenger new energy vehicle market. Beyond Li One, the company expands its product line, including both BEVs and PHEVs, to target a broader consumer base.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.